Oxetanones

A pancreas lipase-inhibiting composition comprising an effective amount of a racemic compound of the formula ##STR26## [wherein R.sup.1 and R.sup.2 are independently C.sub.1-17 -alkyl which is saturated or optionally interrupted by up to 8 double or triple bonds and/or optionally interrupted by an O or S atom which is present in a position other than the .alpha.-position to an unsaturated C-atom;

• or phenyl, benzyl or --C.sub.6 H.sub.4 --X--C.sub.6 H.sub.5 ring-substituted by 0 to 3 C.sub.1-6 -alkyl-(O or S).sub.1 or 0 groups, X is oxygen, sulfur or (CH.sub.2).sub.0-3, R.sup.3 is hydrogen, C.sub.1-3 -alkyl or C.sub.1-3 -alkanoyl, R.sup.4 is hydrogen or C.sub.1-3 -alkyl, and R.sup.5 is hydrogen, a group Ar or Ar-C.sub.1-3 -alkyl or C.sub.1-7 -alkyl optionally interrupted by Y and optionally substituted by Z, or R.sup.4 forms with R.sup.5 a 4- to 6-membered saturated ring, Y is oxygen, sulfur or a group N(R.sup.6), C(O)N(R.sup.6) or N(R.sup.6)C(O), Z is a group --(O or S)--R.sup.7, --N(R.sup.7, R.sup.8), --C(O)N(R.sup.7, R.sup.8) or --N(R.sup.7)C(O)R.sup.8, n is the number 1 or 0, with the proviso that R.sup.5 is hydrogen when n is the number 1, Ar is phenyl which is unsubstituted or substituted by up to 3 groups R.sup.9 or OR.sup.9, and R.sup.6, R.sup.7, R.sup.8 and R.sup.9 individually are hydrogen or C.sub.1-3 -alkyl, with the proviso that R.sup.4 is other than hydrogen when R.sup.3 is formyl and R.sup.5 is isobutyl or R.sup.3 is acetyl and R.sup.5 is carbamoylmethyl, and simultaneously R.sup.2 is undecyl or 2,5-undecadienyl and R.sup.1 is n-hexyl,] wherein R.sup.1 is methyl, propyl, decyl, hexadecyl, allyl, benzyl or ethyl;
• R.sup.2 is methyl, undecyl, 3-butenyl, 3-undecenyl, 8,11-heptadecadienyl, phenoxyphenyl or heptadecyl;
• R.sup.3 is acetyl or formyl;
• R.sup.4 is methyl or hydrogen and R.sup.5 is hydrogen, methyl, 2-butyl, benzyl, methylthioethyl or i-butyl, or R.sup.4 and R.sup.5 together form a pyrrolidinyl moiety, and n is the number 1 or 0, an enantiomer or a diastereomer thereof, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically inert carrier material.

A method of inhibiting pancreas lipase which comprises administering to a host requiring such treatment an effective amount of a racemic compound of the formula ##STR27## [wherein R.sup.1 and R.sup.2 are independently C.sub.1-17 -alkyl which is saturated or optionally interrupted by up to 8 double or triple bonds and/or optionally interrupted by an O or S atom which is present in a position other than the .alpha.-position to an unsaturated C-atom;

• or phenyl, benzyl or --C.sub.6 H.sub.4 --X--C.sub.6 H.sub.5 ring-substituted by 0 to 3 C.sub.1-6 -alkyl-(O or S).sub.1 or 0 groups, X is oxygen, sulfur or (CH.sub.2).sub.0-3, R.sup.3 is hydrogen, C.sub.1-3 -alkyl or C.sub.1-3 -alkanoyl, R.sup.4 is hydrogen or C.sub.1-3 -alkyl, and R.sup.5 is hydrogen, a group Ar or Ar-C.sub.1-3 -alkyl or C.sub.1-7 -alkyl optionally interrupted by Y and optionally substituted by Z, or R.sup.4 forms with R.sup.5 a 4- to 6-membered saturated ring, Y is oxygen, sulfur or a group N(R.sup.6), C(O)N(R.sup.6) or N(R.sup.6)C(O), Z is a group --(O or S)-- R.sup.7, --N(R.sup.7, R.sup.8), --C(O)N(R.sup.7, R.sup.8) or --N(R.sup.7)C(O)R.sup.8, n is the number 1 or 0, with the proviso that R.sup.5 is hydrogen when n is the number 1, Ar is phenyl which is unsubstituted or substituted by up to 3 groups R.sup.9 or OR.sup.9, and R.sup.6 to R.sup.9 are hydrogen or C.sub.1-3 -alkyl, with the proviso that R.sup.4 is other than hydrogen when R.sup.3 is formyl and R.sup.5 is isobutyl or R.sup.3 is acetyl, and R.sup.5 is carbamoylmethyl, and simultaneously R.sup.2 is undecyl or 2,5-undecadienyl, and R.sup.1 is n-hexyl, wherein R.sup.1 is methyl, propyl, decyl, hexadecyl, allyl, benzyl or ethyl;
• R.sup.2 is methyl, undecyl, 3-butenyl, 3-undecenyl, 8,11-heptadecadienyl, phenoxyphenyl or heptadecyl;
• R.sup.3 is acetyl or formyl;
• R.sup.4 is methyl or hydrogen and R.sup.5 is hydrogen, methyl, 2-butyl, benzyl, methylthioethyl or i-butyl, or R.sup.4 and R.sup.5 together form a pyrrolidinyl moiety, and n is the number 1 or 0, an enantiomer or diastereomer thereof, or a pharmaceutically acceptable acid addition salt thereof.